Cargando…

Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer

BACKGROUND: Pathological complete remission (pCR) of estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer is rarely achieved after neoadjuvant chemotherapy (NAC). In addition, the prognostic value of pCR for this breast cancer subtype is limited. We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Loo, Claudette E., Rigter, Lisanne S., Pengel, Kenneth E., Wesseling, Jelle, Rodenhuis, Sjoerd, Peeters, Marie-Jeanne T. F. D. Vrancken, Sikorska, Karolina, Gilhuijs, Kenneth G. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975876/ https://www.ncbi.nlm.nih.gov/pubmed/27495815 http://dx.doi.org/10.1186/s13058-016-0742-0

Ejemplares similares

Monitoring tumor response to neoadjuvant chemotherapy using MRI and (18)F-FDG PET/CT in breast cancer subtypes
por: Schmitz, Alexander M. Th., et al.
Publicado: (2017)

Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer
por: Rigter, L S, et al.
Publicado: (2013)

Additional value of (18)F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer
por: van Ramshorst, Mette S., et al.
Publicado: (2017)

Prognostic value of breast MRI characteristics before and during neoadjuvant endocrine therapy in patients with ER+/HER2- breast cancer
por: Ragusi, Max AA, et al.
Publicado: (2021)

Contralateral parenchymal enhancement on MRI is associated with tumor proteasome pathway gene expression and overall survival of early ER+/HER2-breast cancer patients
por: Ragusi, Max A.A., et al.
Publicado: (2021)

Contralateral parenchymal enhancement on breast MRI before and during neoadjuvant endocrine therapy in relation to the preoperative endocrine prognostic index
por: Ragusi, Max A. A., et al.
Publicado: (2020)

The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy
por: Straver, M. E., et al.
Publicado: (2010)

Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
por: Groen, Emma J., et al.
Publicado: (2021)

Cost-effectiveness and resource use of implementing MRI-guided NACT in ER-positive/HER2-negative breast cancers in The Netherlands
por: Miquel-Cases, Anna, et al.
Publicado: (2016)

Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients
por: Straver, Marieke E., et al.
Publicado: (2010)

Synchronous Breast Cancer: Phenotypic Similarities on MRI
por: Wang, Hui, et al.
Publicado: (2019)

Volumetric breast density estimation on MRI using explainable deep learning regression
por: van der Velden, Bas H. M., et al.
Publicado: (2020)

Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival
por: van der Voort, Anna, et al.
Publicado: (2022)

Contralateral parenchymal enhancement on dynamic contrast-enhanced MRI reproduces as a biomarker of survival in ER-positive/HER2-negative breast cancer patients
por: van der Velden, Bas H. M., et al.
Publicado: (2018)

Harmonization of Quantitative Parenchymal Enhancement in T(1)‐Weighted Breast MRI
por: van der Velden, Bas H.M., et al.
Publicado: (2020)

Local staging of ipsilateral breast tumor recurrence: mammography, ultrasound, or MRI?
por: Walstra, Coco J. E. F., et al.
Publicado: (2020)

Improving prediction of response to neoadjuvant treatment in patients with breast cancer by combining liquid biopsies with multiparametric MRI: protocol of the LIMA study – a multicentre prospective observational cohort study
por: Janssen, Liselore M, et al.
Publicado: (2022)

Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation
por: Severson, Tesa M., et al.
Publicado: (2016)

Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol
por: van Loevezijn, Ariane A., et al.
Publicado: (2022)

ASO Author Reflections: The Pursuit of Eliminating Surgery after Neoadjuvant Systemic Therapy in Breast Cancer Patients
por: van Loevezijn, Ariane A., et al.
Publicado: (2020)

Biopsy-Guided Pathological Response Assessment in Breast Cancer is Insufficient: Additional Pathology Findings of the MICRA Trial
por: van Hemert, Annemiek K. E., et al.
Publicado: (2023)

Influence of neoadjuvant chemotherapy on diffuse reflectance spectra of tissue in breast surgery specimens
por: de Boer, Lisanne L., et al.
Publicado: (2019)

Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study
por: van Loevezijn, Ariane A., et al.
Publicado: (2020)

Machine Learning Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy for ER+HER2- Breast Cancer: Integrating Tumoral and Peritumoral MRI Radiomic Features
por: Park, Jiwoo, et al.
Publicado: (2023)

MRI to assess response after neoadjuvant chemotherapy in breast cancer subtypes: a systematic review and meta-analysis
por: Janssen, L. M., et al.
Publicado: (2022)

Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
por: Gianni, Luca, et al.
Publicado: (2022)

Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
por: Ryu, Ho Hyun, et al.
Publicado: (2021)

Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response
por: Lips, E. H., et al.
Publicado: (2013)

Breast Cancer Subtype Specific Classifiers of Response to Neoadjuvant Chemotherapy Do Not Outperform Classifiers Trained on All Subtypes
por: de Ronde, Jorma J., et al.
Publicado: (2014)

PTCH1 and CTNNB1 emerge as pivotal predictors of resistance to neoadjuvant chemotherapy in ER+/HER2- breast cancer
por: Ozcan, Gulnihal
Publicado: (2023)

High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial
por: Vliek, Sonja, et al.
Publicado: (2023)

BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
por: Liefaard, M. C., et al.
Publicado: (2023)

Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness
por: Lips, Esther H, et al.
Publicado: (2011)

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
por: Burcombe, R J, et al.
Publicado: (2005)

Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma
por: Peng, Jian-Heng, et al.
Publicado: (2019)

The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2− Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma: Erratum
Publicado: (2022)

Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response
por: Lips, Esther H., et al.
Publicado: (2015)

Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer
por: Katayama, Ayaka, et al.
Publicado: (2021)

MRI-Based Radiomics Approach Predicts Tumor Recurrence in ER + /HER2 − Early Breast Cancer Patients
por: Chiacchiaretta, Piero, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9sebonliiirci7gf25k5itgnvu